Dr. Lal Path Labs Ltd. Asset Resilience Ratio
Dr. Lal Path Labs Ltd. asset resilience ratio. Dr. Lal Path Labs Ltd. (LALPATHLAB) has an Asset Resilience Ratio of 13.43% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See LALPATHLAB cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Dr. Lal Path Labs Ltd. (2011–2026)
Asset resilience ratio of Dr. Lal Path Labs Ltd. from 2011 to 2026. This chart shows how Dr. Lal Path Labs Ltd.'s Asset Resilience Ratio has changed over time. Read LALPATHLAB total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Dr. Lal Path Labs Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see LALPATHLAB total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs4.23 Billion | 13.43% |
| Total Liquid Assets | Rs4.23 Billion | 13.43% |
Asset Resilience Insights
- Moderate Liquidity: Dr. Lal Path Labs Ltd. has 13.43% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Dr. Lal Path Labs Ltd. Industry Peers by Asset Resilience Ratio
Compare Dr. Lal Path Labs Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Vijaya Diagnostic Centre Limited
NSE:VIJAYA |
Diagnostics & Research | 15.15% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Dr. Lal Path Labs Ltd. Asset Resilience Ratio by Year (2011–2026)
Dr. Lal Path Labs Ltd. asset resilience ratio by year from 2011 to 2026. The table below shows the annual Asset Resilience Ratio data for Dr. Lal Path Labs Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 13.43% | Rs4.23 Billion ≈ $45.70 Million |
Rs31.46 Billion ≈ $340.23 Million |
-28.53pp |
| 2025-03-31 | 41.96% | Rs11.40 Billion ≈ $123.29 Million |
Rs27.17 Billion ≈ $293.81 Million |
+4.60pp |
| 2024-03-31 | 37.37% | Rs9.18 Billion ≈ $99.25 Million |
Rs24.56 Billion ≈ $265.60 Million |
+2.26pp |
| 2023-03-31 | 35.11% | Rs8.38 Billion ≈ $90.57 Million |
Rs23.86 Billion ≈ $257.98 Million |
+7.03pp |
| 2022-03-31 | 28.08% | Rs6.61 Billion ≈ $71.45 Million |
Rs23.53 Billion ≈ $254.49 Million |
-29.58pp |
| 2021-03-31 | 57.66% | Rs9.58 Billion ≈ $103.59 Million |
Rs16.61 Billion ≈ $179.67 Million |
+5.29pp |
| 2020-03-31 | 52.37% | Rs7.20 Billion ≈ $77.83 Million |
Rs13.74 Billion ≈ $148.63 Million |
-7.23pp |
| 2019-03-31 | 59.60% | Rs6.50 Billion ≈ $70.28 Million |
Rs10.90 Billion ≈ $117.93 Million |
+7.26pp |
| 2018-03-31 | 52.34% | Rs4.81 Billion ≈ $52.01 Million |
Rs9.19 Billion ≈ $99.37 Million |
+7.70pp |
| 2017-03-31 | 44.65% | Rs3.41 Billion ≈ $36.90 Million |
Rs7.64 Billion ≈ $82.64 Million |
+0.62pp |
| 2016-03-31 | 44.03% | Rs2.75 Billion ≈ $29.77 Million |
Rs6.25 Billion ≈ $67.62 Million |
+9.77pp |
| 2015-03-31 | 34.26% | Rs1.63 Billion ≈ $17.61 Million |
Rs4.75 Billion ≈ $51.40 Million |
+6.24pp |
| 2014-03-31 | 28.02% | Rs984.88 Million ≈ $10.65 Million |
Rs3.52 Billion ≈ $38.02 Million |
+6.11pp |
| 2013-03-31 | 21.91% | Rs589.39 Million ≈ $6.37 Million |
Rs2.69 Billion ≈ $29.09 Million |
+16.13pp |
| 2012-03-31 | 5.78% | Rs102.37 Million ≈ $1.11 Million |
Rs1.77 Billion ≈ $19.15 Million |
-5.43pp |
| 2011-03-31 | 11.21% | Rs190.20 Million ≈ $2.06 Million |
Rs1.70 Billion ≈ $18.35 Million |
-- |
About Dr. Lal Path Labs Ltd.
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomi… Read more